Journal
RADIOLOGIA MEDICA
Volume 124, Issue 4, Pages 259-265Publisher
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s11547-018-0883-6
Keywords
Soft tissue sarcomas; Immune-checkpoint inhibitors; Pembrolizumab; Eribulin; Olaratumab; Targeted therapy
Ask authors/readers for more resources
Soft tissue sarcomas (STSs) represent a rare and heterogeneous group of solid tumours derived from mesenchymal progenitors and account for 1% of all adult malignancies. Although in the last decade anthracycline-based chemotherapy single agent or in combinations has been able to improve clinical benefits, prognosis is still poor and STSs represent an important unmet medical need. Continuous advances in cancer genetics and genomics have contributed to change management paradigms of STSs as it occurred for other solid tumours. Several treatments have been recently developed with the specific aim of targeting different cell pathways and immune-checkpoints that have been recognized to drive tumour progression. The following attempts to provide a review of literature focusing on the available data concerning novel treatments and future prospective for the management of metastatic STSs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available